BLSMBlossomHill Therapeutics
临床阶段生物制药公司，开发靶向癌症的小分子药物
$16发行价
$150M融资额
$16首日收盘
-1.25%首日表现
临床阶段生物制药公司，开发靶向癌症的小分子药物
公司简介（来源：StockAnalysis）
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incor...
51CFO 判断：需具备肿瘤管线估值、合作交易结构设计及国际临床财务规划能力的CFO
管理层与创始团队详情以 SEC 招股书披露为准
你的公司需要这样的 CFO 吗？
51CFO 为你匹配完整经历过美股 IPO 全过程的欧美籍 CFO 及其他 C 级高管。首批人选 48 小时内可见，免费 30 分钟上市人才诊断，24 小时内回复。
预约咨询